Remote Monitoring of COPD Patients Experiencing an Acute Exacerbation Through Health Evaluations Using Wearable Mobile Technology
Launched by DAVID RUTTENS · Mar 17, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how we can better monitor people with Chronic Obstructive Pulmonary Disease (COPD) during episodes when their symptoms get worse, known as acute exacerbations. These episodes can lead to serious health problems and often require hospital visits. The study involves using wearable technology that can track important health information like breathing rates and oxygen levels while patients are at home. By collecting this data, researchers hope to understand how COPD progresses after these flare-ups and develop ways to predict when someone might need medical help, ultimately reducing hospital visits and improving patients' lives.
To participate in this trial, individuals must be adults over 18 years old who have been diagnosed with COPD and are currently needing hospitalization. They also need to be able to speak and understand Dutch and have a smartphone. Participants will wear devices that monitor their health data from the time they are admitted to the hospital and for three months after their discharge. This will help researchers gather valuable information and potentially lead to better care for COPD patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provide signed and dated informed consent
- • Adults older than 18 years of age
- • Previously diagnosed with COPD
- • Speak and understand the Dutch language
- • Need for hospitalization
- Exclusion Criteria:
- • Previous diagnosis of asthma
- • Not in the possession of a smartphone
About David Ruttens
David Ruttens is a dedicated clinical trial sponsor with a robust commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and cutting-edge methodologies, Ruttens oversees a portfolio of clinical studies that span various therapeutic areas. His leadership is characterized by a deep understanding of regulatory frameworks and a collaborative approach, ensuring that trials are conducted with the highest ethical standards and scientific rigor. Through strategic partnerships and a patient-centric ethos, David Ruttens aims to foster advancements in healthcare, ultimately contributing to the development of safe and effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Genk, Limburg, Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported